# US 2010/0143257 A1 · Prevention of Cancers by Immunization

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0143257 A1
- Document ID: US20100143257A1
- Status: Published application
- Kind: A1
- Application number: 12/612,030
- Filed: 2009-11-04
- Published: 2010-06-10
- Earliest claimed: 2007-05-04
- Inventors: Boris Skurkovich; Ellen Millstein; Simon Skurkovich; Melvin Millstein
- Web page: https://patentgrep.com/patent/US20100143257A1

## CPC

- A61K 31/365: Lactones
- A61K 31/12: Ketones
- A61K 39/001188: {NY-ESO}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 40/10: characterised by the cell type used
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/4269: {NY-ESO}
- A61P 35/00: Antineoplastic agents
- C07K 16/30: from tumour cells
- A61K 2039/505: {comprising antibodies}
- A61K 2039/515: {Animal cells}
- A61K 2239/31: characterized by the route of administration
- C07K 2317/21: from primates, e.g. man
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

In healthy subjects, especially the ones with increased risk for developing cancer due to genetic predisposition or other risk factors, cancer can be prevented by immunization with a cancer vaccine. Oncoantigens present in the vaccine preferably are incubated with IFN-γ, IL-2 or both. To prevent cancer recurrence, cancer patients in remission are given a prolonged course of immunizations with a vaccine that includes, for example, oncoantigens in combination with immune competent cells (e.g., bone marrow and T lymphocytes). The bone marrow and T lymphocytes are optionally treated with IFN-γ, IL-2 or both.

## Claims

### Claim 1

A method for cancer prevention, the method comprising:
a. selecting a healthy subject who is cancer-free, has never been diagnosed with cancer and has an intact immune system; and
b. administering to the subject a vaccine, wherein an oncoantigen present in the vaccine is pre-treated with IFN-γ, IL-2 or a combination thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient is at risk for developing cancer in the future.

### Claim 3 (depends on 1)

The method of claim 1, further comprising monitoring the subject for onset of cancer indicators.

### Claim 4 (depends on 1)

The method of claim 1, wherein the oncoantigen is NY-ESO-1.

### Claim 5 (depends on 1)

The method of claim 1, wherein the vaccine includes whole allogeneic cells, extracts from allogeneic cell membranes, extracts from allogeneic cell cytoplasm, polypeptides or DNA.

### Claim 6

A method for preventing cancer recurrence, the method comprising:
a. selecting a cancer patient who has remained in remission from a solid cancer for at least ten months;
b. collecting bone marrow, T lymphocytes or both from the cancer patient; and
c. administering to the patient, at intervals of at least three weeks:
(i) a vaccine that includes an oncoantigen; and
(ii) a portion of the bone marrow, of the T-lymphocytes or of a combination thereof,
thereby preventing cancer recurrence.

### Claim 7 (depends on 6)

The method of claim 6, wherein the oncoantigen is NY-ESO-1.

### Claim 8 (depends on 6)

The method of claim 6, wherein one or more of the oncoantigen, the bone marrow or the T lymphocytes is pre-treated with IFN-γ, IL-2 or both.

### Claim 9 (depends on 6)

The method of claim 6, further comprising storing the bone marrow, T lymphocytes or both for at least two months.

### Claim 10 (depends on 6)

The method of claim 6, wherein step (b) is repeated and administration of (i) and (ii) continues until the patient achieves at least five years of remission.

### Claim 11 (depends on 6)

The method of claim 6, wherein the vaccine is administered subcutaneously and the bone marrow, T lymphocytes or both are administered intravenously.

### Claim 12 (depends on 6)

The method of claim 6, wherein the vaccine includes whole tumor cells or extracts thereof, polypeptides, DNA or any combination thereof.

### Claim 13

A method for preventing cancer recurrence, the method comprising:
a. selecting a patient with solid cancer who is in remission for at least ten months; and
b. administering to the patient a vaccine that includes, or is obtained from, autologous cancer cells, in combination with bone marrow, T lymphocytes, or both, thereby preventing cancer recurrence, wherein the bone marrow, T-lymphocytes or both are collected from the patient.

### Claim 14 (depends on 13)

The method of claim 13, wherein one or more of the vaccine, bone marrow and T lymphocytes are pretreated with IFN-γ, IL-2 or a combination of IFN-γ and IL-2.

### Claim 15

A method for conducting an experiment in animals or in a clinical trial, the method comprising:
a. selecting a group of healthy subjects who have intact immune system and who are at risk for developing a specific type of cancer in the future;
b. administering to the healthy subjects a vaccine containing NY-ESO-1 pre-treated with IFN-γ, IL-2 or both, to obtain an immunized group;
c. monitoring the immunized group with respect to immune indicators or with respect to onset of said specific type of cancer; and
d. comparing the immunized group with a group that has not received the vaccine with respect to incidence of said immune indicators or the incidence of the onset of said specific type of cancer.
